The FDA is encouraging sponsors of clinical trials for cancer drugs to enroll more patients older than 65, beginning with early-stage studies, when it is safe and ethical to do so. In draft guidance, the FDA says older patients should be recruited in early-stage studies "to obtain information on safety, exposure, and response to better inform the study design and dose selection of later phase studies."
FDA pushes for age diversity in cancer drug trials
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.